191 related articles for article (PubMed ID: 15734831)
1. Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas.
Ohlsson G; Moreira JM; Gromov P; Sauter G; Celis JE
Mol Cell Proteomics; 2005 Apr; 4(4):570-81. PubMed ID: 15734831
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up.
Mathis C; Lascombe I; Monnien F; Bittard H; Kleinclauss F; Bedgedjian I; Fauconnet S; Valmary-Degano S
BMC Cancer; 2018 Dec; 18(1):1239. PubMed ID: 30526555
[TBL] [Abstract][Full Text] [Related]
3. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas.
Celis JE; Ostergaard M; Basse B; Celis A; Lauridsen JB; Ratz GP; Andersen I; Hein B; Wolf H; Orntoft TF; Rasmussen HH
Cancer Res; 1996 Oct; 56(20):4782-90. PubMed ID: 8840999
[TBL] [Abstract][Full Text] [Related]
4. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells.
Boiteux G; Lascombe I; Roche E; Plissonnier ML; Clairotte A; Bittard H; Fauconnet S
Int J Cancer; 2009 Apr; 124(8):1820-8. PubMed ID: 19115207
[TBL] [Abstract][Full Text] [Related]
5. Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.
Moreira JM; Ohlsson G; Gromov P; Simon R; Sauter G; Celis JE; Gromova I
Mol Cell Proteomics; 2010 Jan; 9(1):161-77. PubMed ID: 19783793
[TBL] [Abstract][Full Text] [Related]
6. Expression of the tumor suppressor protein 14-3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition.
Moreira JM; Gromov P; Celis JE
Mol Cell Proteomics; 2004 Apr; 3(4):410-9. PubMed ID: 14736829
[TBL] [Abstract][Full Text] [Related]
7. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
Tölle A; Jung M; Lein M; Johannsen M; Miller K; Moch H; Jung K; Kristiansen G
BMC Cancer; 2009 Jul; 9():248. PubMed ID: 19622156
[TBL] [Abstract][Full Text] [Related]
8. Protein abundancy and mRNA levels of the adipocyte-type fatty acid binding protein correlate in non-invasive and invasive bladder transitional cell carcinomas.
Gromova I; Gromov P; Wolf H; Celis JE
Int J Oncol; 1998 Aug; 13(2):379-83. PubMed ID: 9664136
[TBL] [Abstract][Full Text] [Related]
9. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.
Guan YF; Zhang YH; Breyer RM; Davis L; Breyer MD
Neoplasia; 1999 Oct; 1(4):330-9. PubMed ID: 10935488
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical determination of ETS-1 oncoprotein expression in urothelial carcinomas of the urinary bladder.
Sari A; Calli A; Gorgel SN; Altinboga AA; Kara C; Dincel C; Cakalagaoglu F
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):153-8. PubMed ID: 21623185
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
[TBL] [Abstract][Full Text] [Related]
12. Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness.
Karasavvidou F; Barbanis S; Pappa D; Moutzouris G; Tzortzis V; Melekos MD; Koukoulis G
Arch Pathol Lab Med; 2008 Dec; 132(12):1912-5. PubMed ID: 19061289
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma.
Tölle A; Suhail S; Jung M; Jung K; Stephan C
BMC Cancer; 2011 Jul; 11():302. PubMed ID: 21767383
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
[TBL] [Abstract][Full Text] [Related]
15. DDX39 acts as a suppressor of invasion for bladder cancer.
Kato M; Wei M; Yamano S; Kakehashi A; Tamada S; Nakatani T; Wanibuchi H
Cancer Sci; 2012 Jul; 103(7):1363-9. PubMed ID: 22494014
[TBL] [Abstract][Full Text] [Related]
16. Mammary derived growth inhibitor is not a distinct protein but a mix of heart-type and adipocyte-type fatty acid-binding protein.
Specht B; Bartetzko N; Hohoff C; Kuhl H; Franke R; Börchers T; Spener F
J Biol Chem; 1996 Aug; 271(33):19943-9. PubMed ID: 8702709
[TBL] [Abstract][Full Text] [Related]
17. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression.
DeGraff DJ; Cates JM; Mauney JR; Clark PE; Matusik RJ; Adam RM
Urol Oncol; 2013 Aug; 31(6):802-11. PubMed ID: 21924649
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder.
Luo JH; Hua WF; Rao HL; Liao YJ; Kung HF; Zeng YX; Guan XY; Chen W; Xie D
Cancer Sci; 2009 May; 100(5):896-902. PubMed ID: 19298601
[TBL] [Abstract][Full Text] [Related]
19. FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression.
Lloreta J; Font-Tello A; Juanpere N; Frances A; Lorenzo M; Nonell L; de Muga S; Vázquez I; Cecchini L; Hernández-Llodrà S
Hum Pathol; 2017 Apr; 62():222-231. PubMed ID: 28087474
[TBL] [Abstract][Full Text] [Related]
20. ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder.
Keymoosi H; Gheytanchi E; Asgari M; Shariftabrizi A; Madjd Z
Asian Pac J Cancer Prev; 2014; 15(5):2013-20. PubMed ID: 24716927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
